@FierceBiotech: More than 1/3 of clinical trials conducted by pharma cos. are now being outsourced, says a Kalorama report. Story | Follow @FierceBiotech
@JohnCFierce: Proposed "model" plan would restrict portions of sensitive studies to "legitimate scientists." Via WSJ: News | Follow@JohnCFierce
@RyanMFierce: Seattle's biotech scene lacked startup activity in '11 but didn't want for M&A action. via @ldtimmerman. Article | Follow@RyanMFierce
> Palo Alto, CA-based Neuraltus has reportedly raised close to $10 million in a new round. The biotech is developing a treatment for Lou Gehrig's disease. Story
> Roche has submitted its European application for vismodegib, a new treatment for advanced basal cell carcinoma. Roche release
> PTC Therapeutics has banked a $5 million discovery grant from the Wellcome Trust to support its work on a new antibiotic. Release
> Transcept Pharmaceuticals has received a $10 million milestone payment from Purdue Pharma in connection with the listing of Intermezzo formulation patents in the FDA Orange Book. Release
Pharma News
@FiercePharma: Actavis CEO says generics biz "as we know it" is doomed as company launches branded pain drug in U.S. Release | Follow@FiercePharma
> U.S. officials seek execution drugs in India. Report
> Eyeing diagnostics growth, Roche up for $3B deal. Story
> Actavis CEO: Today's generics business is doomed. Item
> SC judge upholds $327M fine in Risperdal 'doctor letter' case. News
> J&J pulls 12M Motrin bottles as recalls lawsuit gets green light. Report
Vaccines News
> Pfizer, GSK to provide more discount vaccines for GAVI. Story
> Oxford researchers find malaria vaccine target. Article
> Canadian researcher gets FDA ok for HIV vaccine trial. Report
> Sanofi to relaunch Shan5 in 2013. Story
Manufacturing News
> FDA cites Akzo for contamination, leaky equipment. News
> Counterfeiter with Chinese connections is busted. Story
> Daiichi grimaces at Ranbaxy, FDA consent decree. Report
> Trout forges ahead on Novartis-MIT continuous processing effort. Article
And Finally... Editors at two prominent science publications are considering a "model" arrangement under which they may print part of the new research on a more lethal variety of bird flu and hold sensitive sections in a special repository that could only be accessed by "legitimate" scientists. An advisory panel has voiced concerns that terrorists could use the information to make a lethal virus capable of triggering a worldwide pandemic. Story